WHO ICTRP trial
Intravitreal Brolucizumab in management of Chronic Central Serous…
CTRI/2023/06/053778 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2023/06/053778 |
|---|---|
| Public title | Intravitreal Brolucizumab in management of Chronic Central Serous Chorioretinopathy |
| Scientific title | A Randomized, Placebo-controlled Study of the Efficacy, Safety & Tolerability of Intravitreal Brolucizumab in patients with Chronic Central Serous Chorioretinopathy with persistent fluid in the absence of choroidal neovascular membrane - BRICS |
| Primary sponsor | L V Prasad Eye Institute |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: H32- Chorioretinal disorders in diseases classified elsewhere |
| Interventions | Intervention1: Intravitreal Brolucizumab: 6mg/0.05 ml Intravitreal Brolucizumab at baseline and follow up when indicated. Duration is 1 year Control Intervention1: Oral Multivitamin: Oral multivitamins (placebo group) on a daily basis for… |
| Registration date | Dec 6, 2023 |
| Target size | 42 |
| Secondary IDs | LVPEI_CSCR_11 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: